Nageatte Ibrahim, M.D., an internationally recognized oncology drug development leader and immuno-oncology expert, has been appointed as Research Director of Developmental Therapeutics and Immuno-Oncology for HonorHealth Research Institute.
Dr. Ibrahim brings to HonorHealth Research Institute a distinguished career spanning academic oncology, translational research, and global cancer drug development. She trained in hematology and oncology, completed research fellowships in melanoma and breast cancer, and held faculty appointments at Harvard Medical School/Dana-Farber Cancer Institute and the University of Pennsylvania’s Perelman School of Medicine/Abramson Cancer Center.
She later established herself as a leader in biopharma oncology drug development, including as Vice President of Global Clinical Development, Oncology, at Merck, where she helped guide the strategy and execution of Keytruda and Keytruda-based combinations across multiple tumor types. Her work has supported major oncology advances and global approvals across melanoma, Merkel cell carcinoma, gastrointestinal and hepatobiliary cancers, and tumor-agnostic biomarker-driven indications, including MSI-H/dMMR and TMB-H cancers.
Dr. Ibrahim’s broader development experience spans immuno-oncology, targeted therapies, antibody-drug conjugates, and small molecules.